Background. Peyronie’s disease is a disease characterized by chronic inflammation of the protein membrane of the fibrous tissue of the penis. Oral pharmacotherapy allows a long-term effect on the mechanisms of formation of fibrous plaque.Aim. To evaluate the degree of change in complaints against the background of the complex drug Peyroflex® and its effectiveness.Materials and methods. The study was conducted as a prospective observational study. The study included 43 patients with complaints of pain in the penis area during erection or at rest, curvature of the penis, the presence of palpable plaque in the area of the cavernous bodies. Men took Peyroflex® on a regular basis, one capsule (410 mg) 2 times a day for 6 months or until the pain disappeared during erection, but not less than 6 months.Results. The intensity of pain after 3 and 6 months of taking Peyroflex® decreased by 47.8 and 78.3 %, respectively. The severity of penile curvature showed a tendency to decrease by 7.5 % after 3 doses of Peyroflex® and remained stable after 6 months. The plaque area according to the results of ultrasound examination after 3 and 6 months of taking Peyroflex® decreased by 14.7 and 17.2 %, respectively.Conclusion. Peyroflex® can be recommended for use in the active phase of Peyronie’s disease both in monotherapy and in combination with other methods of treatment (extracorporeal shock wave therapy, physiotherapy, etc.).

The article is devoted to the study of the effectiveness of low-intensity extracorporal shockwave therapy in the treatment of Peyronie disease. Fibroplastic induration of the penis, i.e Peyronie disease, is the one with poorly studied aetiology and pathogenesis. Treatment algorithm also needs to be studied. Literature review was performed. Examination and treatment of patients with the use of low-intensity extracorporeal shock wave therapy was performed. The results of our own research have confirmed the high efficiency and safety of the method.